Moreover, the chemotherapy effect of irinotecan combined with CQ treatment on the tumor in SW620 SOX2 KD group is better than that in the SW620 control group, suggesting that SOX2 knockdown may increase tumor chemosensitivity in vivo. This evidence concerns the gene SOX2 and neoplasm.